Neither the NPS Pharmaceuticals Board of Directors nor any other person makes any recommendation as to whether holders of notes should tender their notes, and no one has been authorized to make such a recommendation. Holders of notes must make their own decisions as to whether to tender their notes, and, if they decide to do so, the principal amount of notes to tender.
This announcement is not an offer to buy or the solicitation of an offer to sell any notes. The tender offer for NPS Pharmaceuticals' 3.0% Convertible Notes due 2008 will be made solely by and subject to the terms and conditions set forth in a Schedule TO (including an offer to purchase, related letter of transmittal and other tender offer documents) that is being filed by NPS Pharmaceuticals today with the Securities and Exchange Commission. The Schedule TO will contain important information and should be read carefully before any decision is made with respect to the tender offer. The offer to purchase, letter of transmittal and other tender offer documents are being delivered to holders of the notes. Once the Schedule TO and other documents are filed with the SEC, they will be available free of charge on the SEC's website at http://www.sec.gov, on NPS Pharmaceuticals' website at http://www.npsp.com or by contacting the NPS Pharmaceuticals Corporate Secretary at (800) 730-3644.
NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant
proteins as drugs, primarily for the treatment of metabolic, bone and
mineral, and central nervous system disorders. The company has drug
candidates in various stages of clinical development. Additional
information is available on the company's website, '/>"/>
|SOURCE NPS Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved